首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   101020篇
  免费   9682篇
  国内免费   4050篇
耳鼻咽喉   386篇
儿科学   2104篇
妇产科学   1237篇
基础医学   17049篇
口腔科学   1295篇
临床医学   8055篇
内科学   22069篇
皮肤病学   1671篇
神经病学   4626篇
特种医学   2271篇
外国民族医学   15篇
外科学   9137篇
综合类   14242篇
现状与发展   24篇
一般理论   2篇
预防医学   7327篇
眼科学   760篇
药学   11971篇
  22篇
中国医学   4395篇
肿瘤学   6094篇
  2023年   1390篇
  2022年   2257篇
  2021年   3467篇
  2020年   3467篇
  2019年   4081篇
  2018年   3830篇
  2017年   3753篇
  2016年   4013篇
  2015年   4378篇
  2014年   6946篇
  2013年   6908篇
  2012年   6802篇
  2011年   7370篇
  2010年   6074篇
  2009年   5566篇
  2008年   5440篇
  2007年   5124篇
  2006年   4533篇
  2005年   3991篇
  2004年   3340篇
  2003年   2813篇
  2002年   2273篇
  2001年   1994篇
  2000年   1613篇
  1999年   1360篇
  1998年   1079篇
  1997年   942篇
  1996年   741篇
  1995年   824篇
  1994年   691篇
  1993年   578篇
  1992年   538篇
  1991年   453篇
  1990年   398篇
  1989年   351篇
  1988年   298篇
  1987年   262篇
  1986年   201篇
  1985年   565篇
  1984年   586篇
  1983年   478篇
  1982年   488篇
  1981年   424篇
  1980年   377篇
  1979年   360篇
  1978年   268篇
  1977年   223篇
  1976年   220篇
  1975年   192篇
  1974年   154篇
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
51.
目的:探讨中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对初治前弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)患者预后的意义。方法:回顾性分析2010年1月至2019年10月,新疆医科大学附属肿瘤医院收治的165例初治DLBCL患者,确定了NLR(>2.77)在预后预测中的最佳临界值,采用Log-rank检验和Cox回归模型进行分析,评价治疗前NLR对无进展生存期(progression free survival time,PFS)和总生存期(overall survival rate,OS)的影响。结果:在入选的165例患者中,有67例患者治疗前NLR升高(>2.77),NLR升高与PFS和OS较短的患者明显相关(P<0.001和P=0.003)。多变量分析进一步表明,NLR>2.77是PFS的独立预测因子。结论:治疗前NLR升高提示DLBCL患者预后不良。  相似文献   
52.
53.
54.
55.
56.
The predictive role of noninvasive liver fibrosis scores on liver-related mortality in patients with chronic hepatitis B below 40 years of age remains unclarified. We examined the association of liver fibrosis scores with liver-related mortality in young (<40 years) and older adults with hepatitis B virus (HBV) infection. A cohort study was performed in 21,360 HBsAg-positive Korean adults without liver cirrhosis or liver cancer at baseline who were followed up for up to 18 years. The liver fibrosis scores were determined using the fibrosis-4 score (FIB-4) and aspartate transaminase to platelet ratio index (APRI). Patients’ vital status and cause of death were ascertained through the National Death Records. During a median follow-up of 10.2 years, 283 liver-related deaths were identified (liver-related mortality, 127.4/105 person-years). The liver fibrosis scores were significantly associated with increased risks of liver-related mortality; this association did not differ by age group (<40 vs. ≥40 years). The multivariable-adjusted hazard ratios with 95% confidence intervals for liver-related mortality comparing intermediate and high to low FIB-4 scores were 4.23 (1.99–9.00), and 15.16 (5.18–44.38), respectively, among individuals under 40, and 4.46 (3.03–6.56) and 22.47 (15.11–33.41), respectively, among older individuals. These associations were similar in analyses using APRI. In this cohort of HBsAg-positive individuals, the liver fibrosis scores were associated with increased risks of liver-related mortality in young and older adults. The liver fibrosis scores have a role in predicting liver mortality, even in young adults with HBV.  相似文献   
57.
Hepatitis B virus (HBV) DNA is detectable in the nails and hair of patients with chronic HBV infection. However, it remains unclear whether HBV DNA can be detectable in the nails and hair of patients with acute HBV infection. We encountered two cases of children with acute HBV infection. HBV DNA in the nails and hair from the two children was evaluated by real-time PCR. To clarify the characteristics of HBV DNA, full-length HBV genome sequencing and phylogenetic tree analysis were performed. The levels of serum HBV DNA in children of cases 1 and 2 at day 0 were 7.6 Log IU/mL and 7.4 Log IU/mL, respectively. Nail HBV DNA was detected in both children (case 1: 4.6 Log IU/mL at day 0, case 2: 5.5 Log IU/mL at day 14). Moreover, hair HBV DNA was detectable in case 2 (4.0 Log IU/mL at day 14). Serum HBV DNA became undetectable within approximately 3–4 months after the first hospital visit. After the resolution of HBV viremia, nail and hair HBV DNA became undetectable. The sequence analysis of serum, nail and hair HBV DNA showed the same HBV genotype in each case (case1: genotype C, case 2: genotype A). In case 1, 3 nucleotides were different in the full-genome HBV sequence between the serum and nails. In case 2, the full-genome HBV sequences were identical among the serum, nails and hair. In conclusion, HBV DNA was detectable in nails and hair of children with acute HBV infection.  相似文献   
58.
BackgroundIncreased hip adduction and internal rotation can lead to excessive patellofemoral joint stress and contribute to patellofemoral pain development. The gluteus maximus acts as a hip extensor, abductor, and external rotator. Improving hip extensor use by increasing one’s forward trunk lean in the sagittal plane may improve frontal and transverse plane hip kinematics during stair ascent.Research questionDoes increasing forward trunk lean during stair ascent affect peak hip adduction and internal rotation?MethodsTwenty asymptomatic females performed five stair ascent trials (96 steps/min) on an instrumented stair using their self-selected and forward trunk lean postures. Three-dimensional kinematics (200 Hz) and kinetics (2000 Hz) were recorded during the stance phase of stair ascent. Biomechanical dependent variables were calculated during the stance phase of stair ascent and included peak forward trunk lean, hip flexion, hip adduction, hip internal rotation angles, and the average hip extensor moment.ResultsDuring the forward trunk lean condition, decreases were observed for peak hip adduction (MD = 2.8˚; 95% CI = 1.9, 3.8; p < 0.001) and peak hip internal rotation (MD = 1.1˚; 95% CI = 0.1, 2.2; p = 0.04). In contrast, increases were observed during the forward trunk lean condition for the peak forward trunk lean angle (MD = −34.7˚; 95% CI = −39.1, −30.3; p < 0.001), average hip extensor moment (MD = −0.5 N·m/kg; 95% CI = −0.5, −0.4; p < 0.001), and stance time duration (MD = −0.02 s; 95% CI = −0.04, 0.00; p = 0.017).SignificanceIncreasing forward trunk lean and hip extensor use during stair ascent decreased peak hip adduction and internal rotation in asymptomatic females. Future studies should examine the effects of increasing forward trunk lean on hip kinematics, self-reported pain, and function in individuals with patellofemoral pain.  相似文献   
59.
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction.  相似文献   
60.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号